{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:55:59Z","timestamp":1784645759966,"version":"3.55.0"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cyclobenzaprine, a centrally-acting muscle relaxant, is widely used for the treatment of musculoskeletal pain. Despite its efficacy, concerns regarding its safety profile, particularly adverse events (AEs), have been increasingly reported. This study aims to comprehensively analyze cyclobenzaprine-related AEs using the FDA Adverse Event Reporting System (FAERS) database to identify potential safety signals and inform clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective pharmacovigilance study was conducted using FAERS data from Q1 2004 to Q3 2024. Reports involving cyclobenzaprine as the primary suspect drug were analyzed. Descriptive statistics and disproportionality analyzes, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multinomial Gamma Poisson Shrinkage (MGPS), were employed to detect safety signals. Subgroup analyzes were performed to explore demographic heterogeneity. Furthermore, the Weibull distribution was utilized to construct a model for the risk of adverse events as time progresses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 18,289,374 AE reports, 2,425 were linked to cyclobenzaprine. Employing four distinct computational approaches at the preferred term (PT) level, we pinpointed 1,100 PTs signifying remarkable adverse reactions. The adverse reactions listed on the drug\u2019s label, like cardiac arrest, respiratory arrest, drug hypersensitivity, dizziness, and somnolence, presented conspicuous signals. In addition, we discovered potential adverse reactions not detailed on the label, for example, toxicity to various agents, completed suicide, drug abuse, overdose, drug interaction, and confusional state. Subgroup analysis brought to light gender\u2014specific AEs. Males had a higher likelihood of experiencing delirium and hallucinations, whereas females were more inclined to encounter drug hypersensitivity and muscle spasms. The vast majority of these AEs were reported during the first month of cyclobenzaprine treatment, with a median onset time of 7\u202fdays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study confirms known AEs associated with cyclobenzaprine and identifies new potential risks, such as toxicity and suicidal behavior. These findings underscore the need for enhanced monitoring and further research to mitigate risks, particularly in vulnerable populations. Clinicians should remain vigilant for both somatic and psychiatric AEs when prescribing cyclobenzaprine, especially in patients with a history of mental health issues or substance abuse.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1574395","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:28:37Z","timestamp":1758518917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiakuan","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuihua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0304-3959(00)00361-4","article-title":"Pain as a reason to visit the doctor: a study in Finnish primary health care","volume":"89","author":"M\u00e4ntyselk\u00e4","year":"2001","journal-title":"Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/S2665-9913(23)00098-X","article-title":"Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/j.pain.0000000000001389","article-title":"The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain","volume":"160","author":"Perrot","year":"2019","journal-title":"Pain"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15626","article-title":"Management of pain in children and adolescents with cerebral palsy: a systematic review","author":"Ostojic","year":"2023","journal-title":"Dev Med Child Neurol"},{"key":"ref6","first-page":"8","article-title":"The assessment of musculoskeletal pain","volume":"35","author":"Hawker","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/cns.12486","article-title":"Preclinical assessment of inflammatory pain","volume":"22","author":"Muley","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2471\/BLT.17.204891","article-title":"Reducing the global burden of musculoskeletal conditions","volume":"96","author":"Briggs","year":"2018","journal-title":"Bull World Health Organ"},{"key":"ref9","first-page":"216","article-title":"Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience","volume":"10","author":"Katz","year":"1988","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0014-2999(96)00402-5","article-title":"Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems","volume":"311","author":"Kobayashi","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/acr.25142","article-title":"Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Lederman","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref12","first-page":"365","article-title":"Choosing a skeletal muscle relaxant","volume":"78","author":"See","year":"2008","journal-title":"Am Fam Physician"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tvjl.2018.05.004","article-title":"The neurobiology of acute pain","volume":"237","author":"Bell","year":"2018","journal-title":"Vet J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jpainsymman.2004.05.002","article-title":"Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review","volume":"28","author":"Chou","year":"2004","journal-title":"J Pain Symptom Manag"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1592\/phco.28.2.207","article-title":"Skeletal muscle relaxants","volume":"28","author":"See","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"ref17","article-title":"Cyclobenzaprine in the treatment of low back pain","volume":"93","author":"Chaffee","year":"2016","journal-title":"Am Fam Physician"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/S0149-2918(03)80067-X","article-title":"Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials","volume":"25","author":"Borenstein","year":"2003","journal-title":"Clin Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3810\/pgm.2010.07.2182","article-title":"Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis","volume":"122","author":"Weil","year":"2010","journal-title":"Postgrad Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1185\/03007990902851753","article-title":"Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design","volume":"25","author":"Malanga","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of Olaparib: data Mining of the Public Version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e27529","DOI":"10.1016\/j.heliyon.2024.e27529","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database","volume":"154","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1458438","DOI":"10.3389\/fphar.2024.1458438","article-title":"Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with Secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","article-title":"Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0036933020946336","article-title":"Sedentarism and chronic disease risk in COVID 19 lockdown \u2013 a scoping review","volume":"66","author":"Chandrasekaran","year":"2021","journal-title":"Scott Med J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.3390\/ijerph18105251","article-title":"Changes in physical activity and sedentary behaviour due to enforced COVID-19-related lockdown and movement restrictions: a protocol for a systematic review and Meta-analysis","volume":"18","author":"Kite","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.bioeng.4.092101.122107","article-title":"Spine ergonomics","volume":"4","author":"Pope","year":"2002","journal-title":"Annu Rev Biomed Eng"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/healthcare10061130","article-title":"Understanding the needs and priorities of people living with persistent pain and long-term musculoskeletal conditions during the COVID-19 pandemic-a public involvement project","volume":"10","author":"Fowler Davis","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/0736-4679(95)02019-5","article-title":"Five-year multicenter retrospective review of cyclobenzaprine toxicity","volume":"13","author":"Spiller","year":"1995","journal-title":"J Emerg Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3109\/14767058.2013.850663","article-title":"Maternal use of cyclobenzaprine (Flexeril) may induce ductal closure and persistent pulmonary hypertension in neonates","volume":"27","author":"Moreira","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ajem.2010.01.014","article-title":"Incidence of tricyclic antidepressant-like complications after cyclobenzaprine overdose","volume":"29","author":"Bebarta","year":"2011","journal-title":"Am J Emerg Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/0024-3205(78)90658-6","article-title":"Cyclobenzaprine: some pharmacological cardiac actions","volume":"23","author":"Hughes","year":"1978","journal-title":"Life Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3109\/15563650.2015.1040157","article-title":"Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: case report","volume":"53","author":"Chua-Tuan","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/ther.2015.0006","article-title":"Use of an intravascular heat exchange catheter and intravenous lipid emulsion for hypothermic cardiac arrest after cyclobenzaprine overdose","volume":"5","author":"Westrol","year":"2015","journal-title":"Ther Hypothermia Temp Manag"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.3390\/ijms24065378","article-title":"Chronic pain-associated cardiovascular disease: the role of sympathetic nerve activity","volume":"24","author":"Reynolds","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e19114","DOI":"10.7759\/cureus.19114","article-title":"\"feeling the blues\": a case of Calcium Channel blocker overdose managed with methylene blue","volume":"13","author":"Pellegrini","year":"2021","journal-title":"Cureus"},{"key":"ref43","first-page":"S21","article-title":"Pharmacologic management of chronic pain","volume":"102","author":"Argoff","year":"2002","journal-title":"J Am Osteopath Assoc"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"115249","DOI":"10.1016\/j.intimp.2025.115249","article-title":"Cyclobenzaprine HCl ameliorates OVA-induced asthma through modulating the TLR4\/MyD88\/NF-\u03baB and PI3K\/AKT\/mTOR signaling pathways","volume":"163","author":"Zhu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.clinthera.2004.09.008","article-title":"Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone","volume":"26","author":"Toth","year":"2004","journal-title":"Clin Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/0002512-200926020-00001","article-title":"Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study","volume":"26","author":"Darwish","year":"2009","journal-title":"Drugs Aging"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1124\/jpet.121.000998","article-title":"The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors","volume":"380","author":"Singh","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archinte.160.9.1373","article-title":"Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine","volume":"160","author":"Douglass","year":"2000","journal-title":"Arch Intern Med"},{"key":"ref49","first-page":"763","article-title":"First episode psychosis following cyclobenzaprine use","volume":"45","author":"O'Neil","year":"2000","journal-title":"Can J Psychiatr"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"115764","DOI":"10.1016\/j.psychres.2024.115764","article-title":"A phase 3, randomized, placebo-controlled, trial to evaluate the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder","volume":"334","author":"Parmenter","year":"2024","journal-title":"Psychiatry Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"eLife"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pbb.2019.03.008","article-title":"Single nucleotide polymorphisms, variable number tandem repeats and allele influence on serotonergic enzyme modulators for aggressive and suicidal behaviors: a review","volume":"180","author":"Xiang","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0014-2999(02)02735-8","article-title":"Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors","volume":"458","author":"Honda","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"bcr2013008997","DOI":"10.1136\/bcr-2013-008997","article-title":"Neuropsychiatric side effects of cyclobenzaprine","volume":"2013","author":"Shprecher","year":"2013","journal-title":"BMJ Case Rep"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuropharm.2013.02.005","article-title":"The two faces of the pharmacological interaction of mGlu2 and 5-HT\u2082a \u2013 relevance of receptor heterocomplexes and interaction through functional brain pathways","volume":"70","author":"Delille","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/0253-7176.85400","article-title":"Intense suicidal thoughts and self-harm following escitalopram treatment","volume":"33","author":"Khan","year":"2011","journal-title":"Indian J Psychol Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13643-020-01296-8","article-title":"Adverse drug reactions associated with amitriptyline - protocol for a systematic multiple-indication review and meta-analysis","volume":"9","author":"Brueckle","year":"2020","journal-title":"Syst Rev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1021\/acschemneuro.0c00467","article-title":"Classics in chemical neuroscience: amitriptyline","volume":"12","author":"McClure","year":"2021","journal-title":"ACS Chem Neurosci"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.mjt.0000134786.50087.d8","article-title":"A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions","volume":"12","author":"Beebe","year":"2005","journal-title":"Am J Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/01.BRS.0000128258.49781.74","article-title":"The use of muscle relaxant medications in acute low back pain","volume":"29","author":"Bernstein","year":"2004","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/ecp.09.5","article-title":"Cyclobenzaprine: a new look at an old pharmacological agent","volume":"2","author":"Cimolai","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1152\/physrev.00014.2018","article-title":"The neuroscience of drug reward and addiction","volume":"99","author":"Volkow","year":"2019","journal-title":"Physiol Rev"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ebiom.2018.10.052","article-title":"Self-regulation of the dopaminergic reward circuit in cocaine users with mental imagery and neurofeedback","volume":"37","author":"Kirschner","year":"2018","journal-title":"EBioMedicine"},{"key":"ref64","first-page":"669","article-title":"Tricyclic antidepressants and histamine H1 receptors","volume":"54","author":"Richelson","year":"1979","journal-title":"Mayo Clin Proc"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2165\/00023210-199605030-00005","article-title":"Anticholinergic drug abuse and misuse","volume":"5","author":"Marken","year":"1996","journal-title":"CNS Drugs"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/bmj.289.6445.612","article-title":"Anticholinergic drug abuse: a common problem?","volume":"289","author":"Pullen","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/0269881107083809","article-title":"Diphenhydramine abuse and detoxification: a brief review and case report","volume":"23","author":"Thomas","year":"2009","journal-title":"J Psychopharmacol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/cap.2010.0031","article-title":"The importance of taking a history of over-the-counter medication use: a brief review and case illustration of \"PRN\" antihistamine dependence in a hospitalized adolescent","volume":"20","author":"Gracious","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s40211-014-0126-6","article-title":"Psyche and soma: what can the consultation-liaison psychiatrist contribute?","volume":"29","author":"Diefenbacher","year":"2015","journal-title":"Neuropsychiatrie"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/healthcare10091729","article-title":"Collaboration between psychiatrists and other allied medical specialists for the treatment of delusional disorders","volume":"10","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/15374416.2016.1236728","article-title":"Early detection and prevention of mental health problems: developmental epidemiology and systems of support","volume":"45","author":"Costello","year":"2016","journal-title":"J Clin Child Adolesc Psychol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1462510","DOI":"10.3389\/fphar.2025.1462510","article-title":"A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database","volume":"16","author":"Tian","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:28:39Z","timestamp":1758518919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1574395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":72,"alternative-id":["10.3389\/fmed.2025.1574395"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1574395","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"article-number":"1574395"}}